A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial.
John M KaneRoy EshetEran HararyOrna TohamiAnna ElgartHelena KnebelNir SharonMark SuettKelli R FranzenburgGlen L DavisChristoph U CorrellPublished in: CNS drugs (2024)
ClinicalTrials.gov, NCT03893825; 27 March 2019.